加速间歇性θ爆发刺激治疗青少年重性抑郁障碍的随机双盲假对照研究
结果显示a-iTBS组在第11天及1个月随访时HAMD-17减分显著优于假刺激组,但3个月随访时组间差异无统计学意义;焦虑与自评抑郁在所有时间点均显著改善。
要点
- 每日5次a-iTBS连续10天可显著改善青少年非难治性MDD的抑郁症状。
- 疗效在第11天和1个月随访时显著,但3个月随访时减退。
- 焦虑和自评抑郁在所有时间点均显著改善,治疗总体安全。
核心结论
- a-iTBS对青少年非难治性重性抑郁障碍安全有效,但治疗效果在3个月随访时减退。
研究设计与样本
- a-iTBS组每日接受5次1800脉冲iTBS,靶点为左侧背外侧前额叶皮层(MNI坐标:-44, 40, 29),使用神经导航,连续10天;假刺激组使用提供触觉和声音的假线圈。
主要发现
- a-iTBS组HAMD-17减分在第11天显著大于假刺激组(p < .001,Cohen's d = 0.86 [95%CI, 0.38 to 1.33])。
- a-iTBS组HAMD-17减分在1个月随访时显著大于假刺激组(Cohen's d = 0.72 [95%CI, 0.24 to 1.18])。
- 3个月随访时两组HAMD-17减分差异无统计学意义(p = .17,Cohen's d = 0.33 [95%CI, -0.13 to 0.79])。
- a-iTBS组在焦虑和自评抑郁方面所有时间点均显著优于假刺激组(所有p值 < .05)。
关键数值与推荐
- HAMD-17用于评估抑郁严重程度,在基线、第11天、1个月和3个月随访时评定。
- 汉密尔顿焦虑量表与儿童抑郁量表用于评估焦虑和自评抑郁。
临床怎么用
- 每日5次a-iTBS连续10天可作为青少年非难治性MDD的安全短期干预选择。
- 需注意疗效在3个月时可能减退,应规划后续维持或随访策略。
- 盲法部分受损(a-iTBS组临床医生识别率超过随机水平),解读结果时需谨慎。
局限性
- 尽管研究为双盲设计,但a-iTBS组临床医生识别率超过随机水平,提示盲法可能部分受损。
- 疗效在3个月随访时减退,长期疗效需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Developing safe and rapid treatments is crucial for adolescent major depressive disorder (MDD). While 10-session daily accelerated intermittent theta burst stimulation (a-iTBS) is effective in adults, its duration and safety limit its use in adolescents. In this study, we evaluated a 5-session daily a-iTBS protocol for adolescents with non-treatment-resistant MDD. METHODS: Seventy-four adolescents with non-treatment-resistant MDD were randomly assigned to a-iTBS or a sham group. The a-iTBS group underwent 5 sessions of 1800-pulse iTBS per day targeting the left dorsolateral prefrontal cortex (Montreal Neurological Institute [MNI] coordinates: -44, 40, 29) using neuronavigation for 10 consecutive days, while the sham group received intervention with a sham coil that provided haptic sensations and audible sounds. The 17-item Hamilton Depression Rating Scale (HAMD-17), Hamilton Anxiety Rating Scale, and Children's Depression Inventory were rated at baseline, the first day after the innervation (day 11), and the 1-month and 3-month follow-ups. RESULTS: The a-iTBS group showed a significantly greater reduction in HAMD-17 scores than the sham group at day 11 (p < .001, Cohen's d = 0.86 [95% CI, 0.38 to 1.33]) and the 1-month follow-up (Cohen's d = 0.72 [95% CI, 0.24 to 1.18]). However, there was no statistically significant difference between the 2 groups at the 3-month follow-up (p = .17, Cohen's d = 0.33 [95% CI, -0.13 to 0.79]). The a-iTBS group showed significantly greater improvements in anxiety and self-reported depression than the sham group at all time points (all p values < .05). CONCLUSIONS: a-iTBS was a safe and effective treatment for adolescents with non-treatment-resistant MDD, but the therapeutic effect diminished at the 3-month follow-up. Although the study was blinded, clinician identification exceeded random chance in the a-iTBS group, which suggests that blinding might have been partially compromised.
引用
- Liu X, Peng Z, Cheng F, et al. Efficacy and Safety of Accelerated Intermittent Theta Burst Stimulation for Adolescents With Major Depressive Disorder: A Randomized, Double-Blind, Sham-Controlled Study. Biol Psychiatry. 2025. PMID: 40738417. doi:10.1016/j.biopsych.2025.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。